TDThomas Daix

Thomas Daix

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Daix has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevated Neutrophil-to-Lymphocyte Ratio Predicts Early Aggravation of Organ Dysfunction in Septic Patients in the Emergency Department

    by Thomas Lafon, Anaëlle Nardot-Suchaud, Julien Vaidie, Thomas Daix, Guillaume Monneret

    OBJECTIVES: To investigate whether neutrophil-to-lymphocyte ratio (NLR), a simple marker of immune dysregulation, is associated with early organ dysfunction progression in emergency department (ED) patients with sepsis. DESIGN: Exploratory secondary analysis of observational clustering cohort. SETTING: Single-center ED. PATIENTS/SUBJECTS: Among 999 patients with adjudicated infection, 364 fulfilled Sepsis-3 criteria for sepsis or septic shock and had available Sequential Organ Failure Assessment (SOFA) scores at admission and 24 hours. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Organ dysfunction trajectory was defined according to the evolution in SOFA score during the first 24 hours (ΔSOFA) and categorized as improving (ΔSOFA ≤ −2), stable (ΔSOFA −1 to +1), or worsening (ΔSOFA ≥ +2). Of the 364 patients, 135 (37%) were classified as improving, 187 (51%) as stable, and 42 (12%) as worsening. NLR differed significantly across trajectory groups, with median values of 12 (7–21), 12 (7–22), and 23 (10–37), respectively ( p = 0.015). In multivariable logistic regression adjusted for age, lactate concentration, and baseline SOFA score, NLR remained independently associated with worsening organ dysfunction trajectory (odds ratio [OR] 5.55, 95% CI, 1.86–18.18; p = 0.003). Patients with worsening trajectories more frequently required ICU admission (26% vs. 5% vs. 4%; p < 0.001) and experienced higher 28-day mortality (36% vs 17% vs 17%; p = 0.013). CONCLUSIONS: NLR was independently associated with early worsening of organ dysfunction in ED patients with sepsis. Beyond its prognostic value, NLR may provide complementary information to conventional severity assessment by reflecting immune dysregulation.

  • Subphenotypes Of Infection In The Emergency Department: Clustering Analysis From Routine Parameters To Predict Early Deterioration

    by Manon Dumolard, Anaëlle Nardot-Suchaud, Henri Hani Karam, Thomas Daix, Thomas Lafon

    Anticipating sepsis and infection-related deterioration in the emergency department (ED) remains challenging due to the limited accuracy of available individual scores and biomarkers. We performed an unsupervised hierarchical cluster analysis using routine variables to identify subphenotypes associated with early deterioration and described their clinical and prognostic features. This retrospective study included patients presented in ED with suspected infection, excluding those without confirmed infection or septic shock. Prognostic phenotypes were identified based on clinical deterioration within 72 hours of admission, as adjudicated by an independent committee. Deterioration was defined by a composite outcome, including an increase in sepsis-related sequential organ failure assessment score ≥ 2 points, subsequent shock requiring full fluid resuscitation, acute respiratory failure needing invasive support, or death. Cluster frequency, characteristics, prognostic performance, and 28- and 90-day mortality were assessed. Among 965 consecutive patients [635 infections; 330 sepsis; mean age = 70 (52–82) years; Charlson score = 4 (1–7); sepsis-related sequential organ failure assessment score = 1 (0–3); lactates = 1.4 (1.1–2.1) mM; D-90 mortality = 11%], deterioration occurred in 155 patients (16%). The clustering analysis identified three phenotypes with distinct clinical and prognostic profiles. Early deterioration occurred in 32% of C#1, 15% of C#2, and 6% of C#3 ( P < 0.001). Cluster 1 (19%) comprised the most severe cases with pronounced organ dysfunction and tissue hypoperfusion. Cluster 2 (56%) showed moderate dysfunction and intermediate outcomes. In contrast, C#3 (25% of patients) represented younger patients with fewer comorbidities and concomitant failures. Recognition of these phenotypes based on available criteria highlights the heterogeneity of sepsis in the ED and may support phenotype-driven risk stratification and clinical management.


  • Open Access

    Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe

    by Holly Jackson, Ana Catalina Hernandez Padilla, Lisanne E. M. Vintcent, Aleksandra Barac, Olaf Cremer, Thomas Daix, Jan J. De Waele, Lorena Forcelledo, Olivier Barraud, Marc J. M. Bonten, et al.

    Background: The clinical and microbiological epidemiology of ventilator-associated pneumonia (VAP) is not well studied in intensive care units (ICUs) European wide. The European Clinical Research Alliance on Infectious Diseases (Ecraid), a warm-base clinical research network investigating infectious diseases, aimed to track the implementation of VAP prevention strategies and quantify the incidence, aetiology, and clinical outcome of VAP, across several European countries. Methods: Overall, 25 ICUs from 11 European countries participating in Ecraid’s perpetual observational study prospectively enrolled adult patients with an expected length of invasive mechanical ventilation (IMV) of at least 48 h, between August 2022 and September 2024. VAP was defined according to the US Food and Drug Administration guidelines. Patients were followed until ICU discharge or 28 days after VAP diagnosis. Routine clinical and microbiological data were prospectively collected. Mortality was calculated using cumulative incidence functions. Results: Of the 3,446 patients at-risk of VAP, 590 developed VAP (cumulative incidence: 17.1%, 95% CI 15.9%-18.4% and incidence rate per 1000 ventilator days: 18.6, 95% CI 17.1–20.1). Importantly, VAP cumulative incidence varied widely between countries recruiting at least 100 patients (range: 7.6% (Croatia)-29.6% (Romania)). Microbiological documentation was available for 359 (60.8%) VAP patients, predominantly showing Staphylococcus aureus (26.2%), Haemophilus influenzae (16.2%), and Pseudomonas aeruginosa (15.0%). Methicillin resistance was confirmed in 14 (18.2%) of 77 VAP cases due to S. aureus . Ceftazidime and carbapenem resistance for P. aeruginosa was reported in 10/46 (21.7%) and 8/47 (17.0%) cases, respectively. Cumulative incidence of ICU mortality was 34.2% (95% CI 30.4%-38.0%) among VAP patients versus 29.3% (95% CI 27.6%-30.9%) in non-VAP patients. The overall median IMV duration until first extubation was 17 days in VAP patients (including ventilation before and after diagnosis) versus 7 days for non-VAP patients. The most widely implemented VAP prevention measure was head-of-bed elevation (3207 patients, 93.1%); only 4 patients (0.1%) did not have any prevention measures implemented. Conclusion: In European ICUs, there is a considerable and heterogeneous incidence of VAP, with methicillin susceptible S. aureus most frequently identified as a causative pathogen. VAP is associated with poor clinical prognosis, highlighting the need for better VAP prevention and management strategies.


  • Open Access

    A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19

    by Manu Shankar-Hari, Bruno Francois, Kenneth E. Remy, Cristina Gutierrez, Stephen Pastores, Thomas Daix, Robin Jeannet, Jane Blood, Andrew H. Walton, Reinaldo Salomao, et al.

    BACKGROUND . Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients’ ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function. METHODS. We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically-ill lymphopenic COVID-19 patients. The primary endpoint was to assess CYT107’s effect on lymphocyte recovery with secondary clinical endpoints including safety, ICU and hospital length-of-stay, incidence of secondary infections, and mortality. RESULTS. CYT107 was well-tolerated without precipitating a cytokine storm or worsening pulmonary function. Absolute lymphocyte counts increased in both groups without significant difference between CYT107 and placebo. COVID-19 patients receiving CYT107 but not concomitant antiviral medications, known inducers of lymphopenia, had a final lymphocyte count that was 43% greater than placebo (p=0.067). There were significantly fewer treatment-emergent adverse events in CYT107 versus placebo-treated patients (pp=0.014). CONCLUSIONS. Given that hospital-acquired infections are responsible for a large percentage of COVID-19 deaths, this effect of CYT107 to decrease nosocomial infections could substantially reduce late morbidity and mortality in this highly lethal disease. The strong safety profile of CYT107 and its excellent tolerability provide support for trials of CYT107 in other potential pandemic respiratory viral infections. TRIAL REGISTRATION. NCT04379076, NCT04426201, NCT04442178, NCT04407689; NCT04927169


  • A program to improve sepsis management in the Emergency Department: a multicenter prospective study in France

    by Anaëlle Nardot, Coralie Lacorre, Antoine Lanneluc, Domitille Paulet, Morgan Gauriat, Cyril Moesch, Pauline Feydeau, Emilie Valantin, Philippe Dupuy, Marine Blondel, et al.

    Implementation of a regional sepsis program to improve compliance with sepsis care bundles and optimize septic patient management and outcomes in the Emergency Department (ED). The program included a multifaceted intervention in 8 EDs: creation of a regional sepsis team, meetings, education (yearly 6-h course and site visits) and sepsis alert. Clinical practice was evaluated in each ED during 1 month every year over 3 years. The primary outcome was the initiation of all criteria of the Surviving Sepsis Campaign (SSC) bundle within 3 h after triage. Secondary outcomes were the initiation of the 3-h bundle in patients with hypotension (SBP ≤ 100 mmHg), admission related to infection or not, proportion of organ supports, subsequent intensive care unit (ICU) admission, and early mortality (day 7). During the 3-month study period, 739 patients were identified with a sepsis including 8% with septic shock. Compliance with the SSC bundle improved during the three periods (P1: 28/176 (16%), P2: 42/272 (15%), P3:69/291 (24%), p = 0.023). In patients with hypotension (n = 142, 19%), no improvement was observed (P1:12/38 (32%), P2:18/46 (39%), P3: 28/58 (48%), p = 0.255). Mortality on day 7 was also similar (10% vs 11% vs 9%, p = 0.621). In multivariate analysis, age (OR = 1.03; 95% CI 1.01–1.05, p = 0.003) and confusion (OR = 2.37; 95% CI 1.37–4.14, p = 0.002) were independently associated with D7 mortality. Patients referred to ED for infection had a better prognosis compared to those with a non-specific reason (OR = 0.56; 95% CI 0.32–0.97, p = 0.038). A regional sepsis educational program appears to improve compliance with the SSC bundle. Pre-hospital identification of sepsis appears to improve further management.


  • Open Access

    Can Biomarkers Correctly Predict Ventilator-associated Pneumonia in Patients Treated With Targeted Temperature Management After Cardiac Arrest? An Exploratory Study of the Multicenter Randomized Antibiotic (ANTHARTIC) Study

    by Nicolas Deye, Amelie Le Gouge, Bruno François, Camille Chenevier-Gobeaux, Thomas Daix, Hamid Merdji, Alain Cariou, Pierre-François Dequin, Christophe Guitton, Bruno Mégarbane, et al.

    IMPORTANCE: Ventilator-associated pneumonia (VAP) frequently occurs in patients with cardiac arrest. Diagnosis of VAP after cardiac arrest remains challenging, while the use of current biomarkers such as C-reactive protein (CRP) or procalcitonin (PCT) is debated. OBJECTIVES: To evaluate biomarkers’ impact in helping VAP diagnosis after cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS: This is a prospective ancillary study of the randomized, multicenter, double-blind placebo-controlled ANtibiotherapy during Therapeutic HypothermiA to pRevenT Infectious Complications (ANTHARTIC) trial evaluating the impact of antibiotic prophylaxis to prevent VAP in out-of-hospital patients with cardiac arrest secondary to shockable rhythm and treated with therapeutic hypothermia. An adjudication committee blindly evaluated VAP according to predefined clinical, radiologic, and microbiological criteria. All patients with available biomarker(s), sample(s), and consent approval were included. MAIN OUTCOMES AND MEASURES: The main endpoint was to evaluate the ability of biomarkers to correctly diagnose and predict VAP within 48 hours after sampling. The secondary endpoint was to study the combination of two biomarkers in discriminating VAP. Blood samples were collected at baseline on day 3. Routine and exploratory panel of inflammatory biomarkers measurements were blindly performed. Analyses were adjusted on the randomization group. RESULTS: Among 161 patients of the ANTHARTIC trial with available biological sample(s), patients with VAP (n = 33) had higher body mass index and Acute Physiology and Chronic Health Evaluation II score, more unwitnessed cardiac arrest, more catecholamines, and experienced more prolonged therapeutic hypothermia duration than patients without VAP (n = 121). In univariate analyses, biomarkers significantly associated with VAP and showing an area under the curve (AUC) greater than 0.70 were CRP (AUC = 0.76), interleukin (IL) 17A and 17C (IL17C) (0.74), macrophage colony-stimulating factor 1 (0.73), PCT (0.72), and vascular endothelial growth factor A (VEGF-A) (0.71). Multivariate analysis combining novel biomarkers revealed several pairs with p value of less than 0.001 and odds ratio greater than 1: VEGF-A + IL12 subunit beta (IL12B), Fms-related tyrosine kinase 3 ligands (Flt3L) + C–C chemokine 20 (CCL20), Flt3L + IL17A, Flt3L + IL6, STAM-binding protein (STAMBP) + CCL20, STAMBP + IL6, CCL20 + 4EBP1, CCL20 + caspase-8 (CASP8), IL6 + 4EBP1, and IL6 + CASP8. Best AUCs were observed for CRP + IL6 (0.79), CRP + CCL20 (0.78), CRP + IL17A, and CRP + IL17C. CONCLUSIONS AND RELEVANCE: Our exploratory study shows that specific biomarkers, especially CRP combined with IL6, could help to better diagnose or predict early VAP occurrence in cardiac arrest patients.


  • Open Access

    De novo natural anti-M alloantibody emergence in severe Coronavirus Disease 2019

    by Robin Jeannet, Alexandra Descazeaud, Thomas Daix, Hélène Pauthier, Virginie Pascal, Sébastien Hantz, Sophie Le Cam, Bruno Francois, Jean Feuillard, Xavier Lafarge


  • Open Access

    High prevalence of infections in non-COVID-19 patients admitted to the Emergency Department with severe lymphopenia

    by Arthur Baïsse, Thomas Daix, Ana Catalina Hernandez Padilla, Robin Jeannet, Olivier Barraud, François Dalmay, Bruno François, Philippe Vignon, Thomas Lafon

    In the Emergency Department (ED), early and accurate recognition of infection is crucial to prompt antibiotic therapy but the initial presentation of patients is variable and poorly characterized. Lymphopenia is commonly associated with bacteraemia and poor outcome in intensive care unit patients. The objective of this retrospective study was to assess the prevalence of community-acquired infection in a cohort of unselected patients admitted to the ED with undifferentiated symptoms and severe lymphopenia. This is a retrospective single-center study conducted over a 1 year-period before the COVID-19 pandemic. Consecutive adult patients admitted to the ED with severe lymphopenia (lymphocyte count < 0.5 G/L) were studied. Patients with hematological or oncological diseases, HIV infection, hepato-cellular deficiency, immunosuppression, or patients over 85 years old were excluded. Diagnoses of infection were validated by an independent adjudication committee. The association between various parameters and infection was assessed using a multivariate logistic regression analysis. Of 953 patients admitted to the ED with severe lymphopenia, 245 were studied (148 men; mean age: 63 ± 19 years). Infection was confirmed in 159 patients (65%) (bacterial: 60%, viral: 30%, other: 10%). Only 61 patients (25%) were referred to the ED for a suspected infection. In the univariate analysis, SIRS criteria (OR: 5.39; 95%CI: 3.04–9.70; p < 0.001) and temperature ≥ 38.3 °C (OR: 10.95; 95%CI: 5.39–22.26; p < 0.001) were strongly associate with infection. In the multivariate analysis, only SIRS criteria (OR: 2.4; 95%CI: 1.48–3.9; p < 0.01) and fever (OR: 3.35; 95%CI: 1.26–8.93; p = 0.016) were independently associated with infection. The prevalence of underlying infection is high in patients admitted to the ED with lymphopenia, irrespective of the reason for admission. Whether lymphopenia could constitute a valuable marker of underlying infection in this clinical setting remains to be confirmed prospectively in larger cohorts. Trial registration: No registration required as this is a retrospective study.


  • New Agents in Development for Sepsis: Any Reason for Hope?

    by Philippe Vignon, Pierre-François Laterre, Thomas Daix, Bruno François

    Sepsis is a syndrome which is defined as a dysregulated host response to infection leading to organ failure. Since it remains one of the leading causes of mortality worldwide, numerous drug candidates have already been tested, and continue to be developed, as potential adjunct therapies. Despite convincing mechanisms of action and robust pre-clinical data, almost all drug candidates in the field of sepsis have failed to demonstrate clinical efficacy in the past two decades. Accordingly, the development of new sepsis drugs has markedly decreased in the past few years. Nevertheless, thanks to a better understanding of sepsis pathophysiology and pathways, new promising drug candidates are currently being developed. Instead of a unique sepsis profile as initially suspected, various phenotypes have been characterised. This has resulted in the identification of multiple targets for new drugs together with relevant biomarkers, and a better understanding of the most appropriate time to intervention. Within the entire sepsis drugs portfolio, those targeting the immune response are probably the most promising. Monoclonal antibodies targeting either cytokines or infectious agents are undoubtedly part of the potential successful therapeutic classes to come.


  • Open Access

    Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients

    by Youenn Jouan, Antoine Guillon, Loïc Gonzalez, Yonatan Perez, Chloé Boisseau, Stephan Ehrmann, Marion Ferreira, Thomas Daix, Robin Jeannet, Bruno François, et al.

    COVID-19 includes lung infection ranging from mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key feature in ARDS pathophysiology. However, cellular actors involved in COVID-19–driven ARDS are poorly understood. Here, in blood and airways of severe COVID-19 patients, we serially analyzed unconventional T cells, a heterogeneous class of T lymphocytes (MAIT, γδT, and iNKT cells) with potent antimicrobial and regulatory functions. Circulating unconventional T cells of COVID-19 patients presented with a profound and persistent phenotypic alteration. In the airways, highly activated unconventional T cells were detected, suggesting a potential contribution in the regulation of local inflammation. Finally, expression of the CD69 activation marker on blood iNKT and MAIT cells of COVID-19 patients on admission was predictive of clinical course and disease severity. Thus, COVID-19 patients present with an altered unconventional T cell biology, and further investigations will be required to precisely assess their functions during SARS–CoV-2–driven ARDS.